(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN- The Fate of Mechanical technology: 5 Headways Forming Tomorrow
- People with depression can treat themselves at home with new device
- The Delight of Perusing: Book Proposals for Each Class
- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Ancient meditation practices find new life in modern religious communities across America
- 8 Espresso Bean Starting points All over the Planet
- Figure out How to Explore the Infotainment Framework in the Slam 1500.
- NASA astronauts take new moonsuit for a swim | Space photo of the day for Nov. 28, 2025
